1
|
Shekhar MS, Venkatachalam T, Sharma CS, Pratap Singh H, Kalra S, Kumar N. Computational investigation of binding mechanism of substituted pyrazinones targeting corticotropin releasing factor-1 receptor deliberated for anti-depressant drug design. J Biomol Struct Dyn 2018; 37:3226-3244. [DOI: 10.1080/07391102.2018.1513379] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
| | - T. Venkatachalam
- Department of Pharmaceutical Chemistry, Annai JKK Sampoorani Ammal College of Pharmacy, Namakkal, Tamil Nadu, India
| | - Chandra Shekhar Sharma
- Department of Pharmaceutical Chemistry, Bhupal Nobles’ College of Pharmacy, Bhupal Nobles’ University, Udaipur, Rajasthan, India
| | - Hemendra Pratap Singh
- Department of Pharmaceutical Chemistry, Bhupal Nobles’ College of Pharmacy, Bhupal Nobles’ University, Udaipur, Rajasthan, India
| | - Sourav Kalra
- Centre for Human Genetics & Molecular Medicine, Central University of Punjab, Bhatinda, Punjab, India
| | - Neeraj Kumar
- Department of Pharmaceutical Chemistry, Geetanjali University, Udaipur, Rajasthan, India
| |
Collapse
|
2
|
Kumar N, Mishra SS, Sharma CS, Singh HP, Kalra S. In silico binding mechanism prediction of benzimidazole based corticotropin releasing factor-1 receptor antagonists by quantitative structure activity relationship, molecular docking and pharmacokinetic parameters calculation. J Biomol Struct Dyn 2017; 36:1691-1712. [PMID: 28521603 DOI: 10.1080/07391102.2017.1332688] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Despite the various research efforts toward the treatment of stress-related disorders, the drug has not yet launched last 20 years. Corticotropin releasing factor-1 receptor antagonists have been point of great interest in stress-related disorders. In the present study, we have selected benzazole scaffold-based compounds as corticotropin releasing factor-1 antagonists and performed 2D and 3D QSAR studies to identify the structural features to elucidating the binding mechanism prediction. The best 2D QSAR model was obtained through multiple linear regression method with r2 value of .7390, q2 value of .5136 and pred_r2 (predicted square correlation coefficient) value of .88. The contribution of 2D descriptor, T_2_C_1 was 60% (negative contribution) and 4pathClusterCount was 40.24% (positive contribution) in enhancing the activity. Also 3D QSAR model was statistically significant with q2 value of .9419 and q2_se (standard error of internal validation) value of .19. Statistical parameters results prove the robustness and significance of both models. Further, molecular docking and pharmacokinetic analysis was performed to explore the scope of investigation. Docking results revealed that the all benzazole compounds show hydrogen bonding with residue Asn283 and having same hydrophobic pocket (Phe286, Leu213, Ile290, Leu287, Phe207, Arg165, Leu323, Tyr327, Phe284, and Met206). Compound B14 has higher activity compare to reference molecules. Most of the compounds were found within acceptable range for pharmacokinetic parameters. This work provides the extremely useful leads for structural substituents essential for benzimidazole moiety to exhibit antagonistic activity against corticotropin releasing factor-1 receptors.
Collapse
Affiliation(s)
- Neeraj Kumar
- a Department of Pharmaceutical Chemistry , Geetanjali College of Pharmacy , Udaipur 313001 , India
| | - Shashank Shekhar Mishra
- b Department of Pharmaceutical Chemistry, Bhupal Nobles' College of Pharmacy , Bhupal Nobles' University , Udaipur 313001 , India
| | - Chandra Shekhar Sharma
- b Department of Pharmaceutical Chemistry, Bhupal Nobles' College of Pharmacy , Bhupal Nobles' University , Udaipur 313001 , India
| | - Hamendra Pratap Singh
- b Department of Pharmaceutical Chemistry, Bhupal Nobles' College of Pharmacy , Bhupal Nobles' University , Udaipur 313001 , India
| | - Sourav Kalra
- c Centre for Human Genetics & Molecular Medicine , Central University of Punjab , Bhatinda 151001 , India
| |
Collapse
|
3
|
Sawai Y, Yabe O, Nakaoka K, Ikemoto T. Process Development of a CRF1 Receptor Antagonist Based on the Selective Chlorination of a Benzimidazolone via Chlorine Migration. Org Process Res Dev 2017. [DOI: 10.1021/acs.oprd.6b00389] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Yasuhiro Sawai
- Process Chemistry, Pharmaceutical
Sciences, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi
2-chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Osamu Yabe
- Process Chemistry, Pharmaceutical
Sciences, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi
2-chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Keiichiro Nakaoka
- Process Chemistry, Pharmaceutical
Sciences, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi
2-chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Tomomi Ikemoto
- Process Chemistry, Pharmaceutical
Sciences, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi
2-chome, Yodogawa-ku, Osaka 532-8686, Japan
| |
Collapse
|
4
|
Mochizuki M, Kori M, Kobayashi K, Yano T, Sako Y, Tanaka M, Kanzaki N, Gyorkos AC, Corrette CP, Cho SY, Pratt SA, Aso K. Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists. J Med Chem 2016; 59:2551-66. [DOI: 10.1021/acs.jmedchem.5b01715] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Michiyo Mochizuki
- Takeda Pharmaceutical Company Ltd., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masakuni Kori
- Takeda Pharmaceutical Company Ltd., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Katsumi Kobayashi
- Takeda Pharmaceutical Company Ltd., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Takahiko Yano
- Takeda Pharmaceutical Company Ltd., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yuu Sako
- Takeda Pharmaceutical Company Ltd., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Maiko Tanaka
- Takeda Pharmaceutical Company Ltd., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Naoyuki Kanzaki
- Takeda Pharmaceutical Company Ltd., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Albert C. Gyorkos
- Array BioPharma Inc., 3200
Walnut Street, Boulder, Colorado 80301, United States
| | | | - Suk Young Cho
- Array BioPharma Inc., 3200
Walnut Street, Boulder, Colorado 80301, United States
| | - Scott A. Pratt
- Array BioPharma Inc., 3200
Walnut Street, Boulder, Colorado 80301, United States
| | - Kazuyoshi Aso
- Takeda Pharmaceutical Company Ltd., 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
5
|
Williams JP. Corticotropin-releasing factor 1 receptor antagonists: a patent review. Expert Opin Ther Pat 2013; 23:1057-68. [DOI: 10.1517/13543776.2013.795545] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
6
|
Denhart DJ, Zuev D, Ditta JL, Hartz RA, Ahuja VT, Mattson RJ, Huang H, Mattson GK, Zueva L, Nielsen JM, Kozlowski ES, Lodge NJ, Bronson JJ, Macor JE. Potential CRF1R PET imaging agents: 1-fluoroalkylsubstituted 5-halo-3-(arylamino)pyrazin-2(1H)-ones. Bioorg Med Chem Lett 2013; 23:2052-5. [PMID: 23465610 DOI: 10.1016/j.bmcl.2013.02.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2012] [Revised: 01/25/2013] [Accepted: 02/01/2013] [Indexed: 11/24/2022]
Abstract
A series of pyrazinones were prepared and evaluated as potential CRF(1)R PET imaging agents. Optimization of their CRF(1)R binding potencies and octanol-phosphate buffer phase distribution coefficients are discussed herein.
Collapse
Affiliation(s)
- Derek J Denhart
- Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Deskus JA, Dischino DD, Mattson RJ, Ditta JL, Parker MF, Denhart DJ, Zuev D, Huang H, Hartz RA, Ahuja VT, Wong H, Mattson GK, Molski TF, Grace JE, Zueva L, Nielsen JM, Dulac H, Li YW, Guaraldi M, Azure M, Onthank D, Hayes M, Wexler E, McDonald J, Lodge NJ, Bronson JJ, Macor JE. [18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agents. Bioorg Med Chem Lett 2012; 22:6651-5. [PMID: 23010264 DOI: 10.1016/j.bmcl.2012.08.112] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2012] [Revised: 08/13/2012] [Accepted: 08/28/2012] [Indexed: 11/25/2022]
Abstract
Based on a favorable balance between CRF-R1 affinity, lipophilicity and metabolic stability, compound 10 was evaluated for potential development as PET radioligand. Compound [(18)F]10 was prepared with high radiochemical purity and showed promising binding properties in rat brain imaging experiments.
Collapse
Affiliation(s)
- Jeffrey A Deskus
- Bristol-Myers Squibb Co., Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Dzierba CD, Sielecki TM, Arvanitis AG, Galka A, Johnson TL, Takvorian AG, Rafalski M, Kasireddy-Polam P, Vig S, Dasgupta B, Zhang G, Molski TF, Wong H, Zaczek RC, Lodge NJ, Combs AP, Gilligan PJ, Trainor GL, Bronson JJ, Macor JE. Synthesis and structure–activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists. Bioorg Med Chem Lett 2012; 22:4986-9. [DOI: 10.1016/j.bmcl.2012.06.034] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2012] [Accepted: 06/11/2012] [Indexed: 10/28/2022]
|
9
|
Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF1) receptor antagonists. Bioorg Med Chem 2012; 20:1122-38. [DOI: 10.1016/j.bmc.2011.11.015] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2011] [Revised: 11/07/2011] [Accepted: 11/08/2011] [Indexed: 11/17/2022]
|
10
|
Saito T, Obitsu T, Kondo T, Matsui T, Nagao Y, Kusumi K, Matsumura N, Ueno S, Kishi A, Katsumata S, Kagamiishi Y, Nakai H, Toda M. 6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists. Bioorg Med Chem 2011; 19:5432-45. [DOI: 10.1016/j.bmc.2011.07.055] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2011] [Revised: 07/23/2011] [Accepted: 07/25/2011] [Indexed: 11/15/2022]
|
11
|
Potential CRF1R PET imaging agents: N-Fluoroalkyl-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethyl-N-alkylpyrazolo[1,5-a][1,3,5]triazin-4-amines. Bioorg Med Chem Lett 2011; 21:2484-8. [DOI: 10.1016/j.bmcl.2011.02.050] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2010] [Revised: 02/09/2011] [Accepted: 02/14/2011] [Indexed: 11/18/2022]
|
12
|
Discovery of pyrrolo[2,3-d]pyrimidin-4-ones as corticotropin-releasing factor 1 receptor antagonists with a carbonyl-based hydrogen bonding acceptor. Bioorg Med Chem Lett 2011; 21:2365-71. [DOI: 10.1016/j.bmcl.2011.02.086] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2011] [Revised: 02/18/2011] [Accepted: 02/21/2011] [Indexed: 11/15/2022]
|
13
|
Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties. Bioorg Med Chem Lett 2010; 20:7259-64. [PMID: 21074436 DOI: 10.1016/j.bmcl.2010.10.095] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2010] [Revised: 10/18/2010] [Accepted: 10/19/2010] [Indexed: 11/20/2022]
Abstract
Antagonists of the corticotropin-releasing factor (CRF) neuropeptide may prove effective in treating stress and anxiety related disorders. In an effort to identify antagonists with improved physico-chemical properties a new series of CRF(1) antagonists were designed to substitute the propyl groups at the C7 position of the pyrazolo[1,5-a]pyrimidine core of 1 with heterocycles. Compound (S)-8d was identified as a high affinity ligand with a pK(i) value of 8.2 and a functional CRF(1) antagonist with pIC(50) value of 7.0 in the in vitro CRF ACTH production assay.
Collapse
|
14
|
5-Arylamino-1,2,4-triazin-6(1H)-one CRF1 receptor antagonists. Bioorg Med Chem Lett 2010; 20:3579-83. [DOI: 10.1016/j.bmcl.2010.04.121] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2010] [Revised: 04/23/2010] [Accepted: 04/27/2010] [Indexed: 11/22/2022]
|
15
|
Zuev D, Vrudhula VM, Michne JA, Dasgupta B, Pin SS, Huang XS, Wu D, Gao Q, Zhang J, Taber MT, Macor JE, Dubowchik GM. Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists. Bioorg Med Chem Lett 2010; 20:3669-74. [DOI: 10.1016/j.bmcl.2010.04.094] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2010] [Revised: 04/20/2010] [Accepted: 04/21/2010] [Indexed: 10/19/2022]
|
16
|
Vrudhula VM, Dasgupta B, Pin SS, Burris KD, Balanda LA, Fung LK, Fiedler T, Browman KE, Taber MT, Zhang J, Macor JE, Dubowchik GM. Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R). Bioorg Med Chem Lett 2010; 20:1905-9. [DOI: 10.1016/j.bmcl.2010.01.127] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2009] [Revised: 01/26/2010] [Accepted: 01/28/2010] [Indexed: 11/30/2022]
|